Puma Biotechnology
PBYI
160 hedge funds and large institutions have $314M invested in Puma Biotechnology in 2026 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 60 increasing their positions, 52 reducing their positions, and 15 closing their positions.
282% more call options, than puts
Call options by funds: $775K | Put options by funds: $203K
44% more capital inflows, than outflows
Capital inflows: $20.7M | Capital outflows: $14.5M
40% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 15
15% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 52
2% more funds holding
Funds holding: 157 → 160 (+3)
1.56% more ownership
Funds ownership: 74.42% → 75.97% (+1.6%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSV Asset Management
Chicago,
Illinois
|
+$3.19M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
+$2.96M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.36M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$1.51M |
| 5 |
BlackRock
New York
|
+$1.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$6.41M |
| 2 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$1.02M |
| 3 |
Renaissance Technologies
New York
|
-$778K |
| 4 |
Morgan Stanley
New York
|
-$689K |
| 5 |
SEI Investments
Oaks,
Pennsylvania
|
-$655K |
PBYI Hedge Fund Activity: Q2 2026 in Review
160 of the 8,352 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q2 2026, worth a combined $314M — up 30% from $242M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new PBYI positions and 15 closed out — a net gain of 6 holders — while 60 added to existing stakes and 52 trimmed.
The largest buyer was LSV Asset Management, adding an estimated $3.19M. The largest seller was Millennium Management, cutting an estimated $6.41M.
- 160 institutional investors held Puma Biotechnology (PBYI) as of Q2 2026, up from 157 in Q1 2026.
- Funds reported $314M of Puma Biotechnology stock for Q2 2026, up 30% quarter-over-quarter.
- 21 funds opened new Puma Biotechnology positions in Q2 2026 and 15 closed out, a net change of +6 holders.
- The largest Puma Biotechnology buyer in Q2 2026 was LSV Asset Management, an estimated $3.19M added.
- The largest Puma Biotechnology seller in Q2 2026 was Millennium Management, an estimated $6.41M sold.
Based on aggregated 13F filings for Q2 2026.